Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines
Additionally, Bpifrance has pledged EUR 15.1M as part of a Projets Structurants Pour la Compétitivité (PSPC) COVID-19 grant to support Osivax’ coronavirus vaccine program